CapricorCAPR
NASDAQ制药
US$8.37+0.00%
关键指标
$2.04B市值
US$40.3752 周最高
US$4.3052 周最低
1,165,11330 日均量
231 员工数57.84M 流通股本上市日期 2002-06-20
下次财报 ~2026年2月2日
关于 Capricor
Capricor Therapeutics Inc是一家临床阶段的生物技术公司，专注于开发变革性的细胞和外泌体疗法，用于治疗杜氏肌营养不良症（DMD），这是一种罕见的肌营养不良症，会导致肌肉退化和过早死亡，以及其他有高未满足医疗需求的疾病。公司的产品管线包括CAP-1002，一种异体心脏来源的细胞疗法deramiocel。Deramiocel目前正处于治疗杜氏肌营养不良症的3期临床开发阶段。通过其专有的StealthXTM平台，该集团利用其外泌体技术进行专注于疫苗学、递送寡核苷酸、蛋白质和小分子治疗的临床前研究。
最新新闻
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kirby McInerney LLP Alerts Investors Who Acquired Capricor Therapeutics, Inc. CAPR Securities Between December 17, 2025 and July 26, 2026 of Pending Lawsuit
NASDAQ: CAPR LAWSUIT ALERT: Investors who lost money with shares of Capricor Therapeutics, Inc.should contact the Shareholders Foundation
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
CAPR Court Alert: Capricor Therapeutics Securities Fraud Class Action Deadline is Approaching on September 28 for Investors that Suffered Losses
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
相关股票制药 行业
想看 CAPR 的实时 AI 观点?
启动实时多智能体分析室 — Claude、GPT、Gemini、DeepSeek、Grok 和 Qwen 同时分析 CAPR,实时输出信号。